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Deep brain stimulation of the subthalamic nucleus or the internal pallidum can be an effective treatment for the disabling motor complications arising from dopaminergic treatment for Parkinson disease. The subthalamic nucleus has emerged as the preferred target for such treatment; however, no data exist to guide the choice between these two sites.
Deep brain stimulation (DBs) can substantially improve motor function and quality of life in selected patients with Parkinson disease (PD) who experience disabling fluctu ations of their motor state and/or severe involuntary movements with dopa minergic therapy. this surgical technique is considered to be interventional neurology par excellence and, as such, is necessarily multidisciplinary, requiring expertise and training in patient selection, meticulous surgery and appropriate postoperative manage ment to maximize benefit and to minimize complications. 1 DBs of the subthalamic nucleus (stn) or the globus pallidus internus (GPi) can improve tremor, akinesia and rigidity in patients with PD. indeed, while subthalamic or pallidal stimulation are no more effective than levodopa at alleviating these symptoms, DBs can provide a more stable level of control than medication, as motor fluctuations are known to occur with the inevitable rise and fall of plasma levodopa levels. the stn is the most commonly targeted site for DBs in PD; however, this preference is based on open studies, experience and convictions. the results of the largest study to date examining bilateral DBs of the stn versus similar stimulation of the GPi in patients with PD have now been published. 2 in the new study, involving seven veterans affairs hospitals and six university hospitals in the us, Follett and colleagues randomized 299 patients with PD (mean age 62 years) to receive stn or GPi DBs. the primary outcome measure was the change in motor function (assessed on the unified Parkinson's Disease rating scale, part iii [uPDrs-iii]) while patients were receiving stimulation but no antiparkinsonian medication. the evaluators were blinded towards the DBs target.
Both patient groups showed similar improvements in motor function (≈25% improvement in off-medication uPDrs-iii scores) and comparable reductions in dyskinesia following DBs. on average, patients from both groups experienced poor motor function 3 h per day and, during these periods, remained dependent-according to assessment by the schwab and england activities of Daily living scale-on the help of a caregiver. overall, only minor cognitive and mood changes were reported over the 2 year follow-up period, with few differences in the nature of these changes between the two groups. medication was reduced by a greater extent and stimulation parameters were lower in the stn than in the GPi group. adverse effects occurred in 50% of patients from both groups.
From the results of their study, Follett and colleagues concluded that patients with PD show similar improvements in motor function with either GPi or stn DBs, and that physicians should freely choose between these targets to deliver neurostimulation. 2 the new study builds on an earlier investigation by these researchers in which they showed that DBs was more effective than best medical therapy at improving motor functions and quality of life in patients with PD at 6 months, but was associated with a higher risk of serious adverse events.
3 in both studies, even though the overall outcomes were favorable with DBs, the risk:benefit ratios for such treatment seemed to be suboptimal when compared with the results of most other studies of neurostimulation in PD.
over a decade of studies from various centers and countries has shown that, on average, patients with PD who undergo subthalamic stimulation have an ≈50% improvement in motor function and an ≈50% decrease in their daily dose of medication by a mean follow-up period of 15 months. several long-term studies, some of which incorporated a doubleblind assessment, have further revealed www.nature.com/nrneurol newS & vIewS that the initial 50% improvement in motor scores can be largely maintained even after several years.
4-6 the level of improvement in motor function and the potential opportunity to decrease dopaminergic medication explain why the stn has become the most widely used DBs target in patients with PD who experience motor fluctuations. in their paper, Follett and colleagues do not discuss the new results in the context of the extensive literature on DBs for PD, which is surprising. the outcome of stn DBs depends on many variables, including patient selection, surgical precision and complications rates, as well as appropriate postoperative management of both electrical and medical treatments. 7 For stn DBs, the extent of preoperative levodopa responsiveness positively correlates with improvement in activities of daily living and motor scores following surgery. 8 thus, a comparison of the preoperative levodopa response and surgical outcome provides a measure of the quality of the DBs team. in a meta-analysis of stn DBs for PD, which examined 921 patients (mean age 59 years) from 37 cohorts, the average non-blinded uPDrs off motor scores after treatment for a mean period of 15 months were 52% better than baseline scores. in most of the studies assessed in this meta-analysis, the ratio of the effect of surgery on motor function to pre operative levodopa responsiveness was close to 1.0. 8 in the study by Follett and colleagues, the average improvement in motor function with DBs (regardless of the target) was ≈25%, while improvement in preoperative off-period motor function with levodopa was ≈50%, giving a surgical:medication ratio close to 0.5. thus, patients in this study continued to have motor fluctuations and remained disabled in the off-drug condition. the reasons why treatment with stn DBs in the Follett et al. study failed to reach the level of efficacy seen in most other trials will require critical analysis by the re searchers involved in the study. the outcome of pallidal stimulation in this study might also be considered as suboptimal since, although applied bilateral ly, pallidal DBs was no more effective than a uni lateral pallidotomy, 9 and led to more adverse events.
the implementation of training for neurolo gists in the management of patients on DBs has been shown to improve outcomes even in a center combining the expertise of the most renowned functional neurosurgeons and PD experts. 10 indeed, multi disciplinary expertise is required to achieve optimal outcomes with this treatment, and DBs seems to fail frequently in centers with little experience of this technique. 7 Drug prescriptions can easily be standardized, allowing generalizations to be made regarding the outcomes of pharmaco logical studies across centers. the outcome of DBs is, however, dependent on successful neurosurgery, which varies in quality among centers. a study that has the primary objective of evaluating the outcome of DBs on two different areas of the brain should at least report data showing that the targeted regions have actually been reached by the DBs electrodes. the constructive and practical lesson from the study by Follett and colleagues is that the optimal benefit of DBs therapy was not reached in the participating centers, and not that GPi DBs shows a similar efficacy to stn DBs in patients with PD. the latter conclusion would risk compromising the quality of treatment provided to patients, who deserve 'state of the art' management.
